Supporting NAD+ levels
The most straightforward reason for taking an interest in NMN is its ability to feed into the body's production of NAD+.
Explore the research →NAD+ PRECURSOR & METABOLIC RESEARCH
NMN
A popular NAD+ precursor being studied for cellular energy, metabolism, physical function and healthy ageing, with a growing body of human research.
NAD+ levelsMetabolic healthEnergy biology
Developing human evidenceHuman trials show target engagement and generally short-term tolerability, while functional and long-term health outcomes remain mixed or uncertain.
FOLLOW THE FULL PICTUREFrom interest to evidence, quality and the numbers.
Why are people interested in NMN?
NMN has become popular in energy and healthy-ageing discussions because the body can use it to make NAD+, a molecule cells rely on for energy and essential maintenance. The interest is therefore broader than simply feeling more energetic — it is also about supporting metabolism, physical function and the cellular processes that become increasingly important with age.
Metabolic health
Blood-sugar control and insulin sensitivity are important areas of NMN research because of NAD+'s wider role in metabolism.
Explore the research →Energy & physical function
People are also interested in NMN for energy, endurance and maintaining physical function, particularly as they get older.
Explore the research →Healthy ageing
Healthy ageing is probably the biggest reason NMN has become so well known outside scientific research.
Explore the research →THE SCIENCE BIT
A building block in the NAD+ recycling system.
NMN sits close to NAD+ in the cell's salvage pathway—the system that rebuilds this essential coenzyme. NMNAT enzymes can convert NMN into NAD+.
The route from an oral supplement to a tissue's NAD pool is more complicated than one direct step. Trials therefore need to measure both biological changes and meaningful outcomes such as muscle or metabolic function.
See the studies & trials →- NMN
- NAD precursor
- NMNAT
- Enzymes that make NAD+
- NAD+
- Cellular energy and regulation
How this connects to the research
Raising a biomarker is separate from demonstrating an anti-ageing benefit.
Read a primary source ↗FROM MOLECULE TO TISSUE
Where NMN connects with the body
These are the tissues and biological systems behind the interest in NMN.
- Cells
- NAD salvage chemistry.
- Muscle
- Metabolic-function research.
- Mitochondria and nucleus
- NAD-dependent processes.
The research behind the interest
Supporting NAD+ levels
The most straightforward reason for taking an interest in NMN is its ability to feed into the body's production of NAD+.
Human trials show that NMN can change NAD-related markers in the body, although the size of the effect varies between studies.
Human biomarker evidenceExplore the studies →Metabolic health
Blood-sugar control and insulin sensitivity are important areas of NMN research because of NAD+'s wider role in metabolism.
Some human studies have reported benefits in particular groups or measurements, but the results are not consistently positive across studies.
Mixed human evidenceExplore the studies →Energy & physical function
People are also interested in NMN for energy, endurance and maintaining physical function, particularly as they get older.
Human findings are mixed, and improvements in physical performance are less consistent than changes in NAD-related blood or tissue markers.
Developing evidenceExplore the studies →Healthy ageing
Healthy ageing is probably the biggest reason NMN has become so well known outside scientific research.
Animal research is extensive, but longer life or a broad anti-ageing effect has not been established in humans.
Preclinical strength · human uncertaintyExplore the studies →Studies & trials
Studies & trials
Original publication · PubMed · trial registry where availableNicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women ↗
25 postmenopausal women with prediabetes who were overweight or obese
OralDaily10 weeks
NMN improved skeletal-muscle insulin sensitivity and insulin-signalling measures compared with placebo.
The study was small and did not show broad improvements across body composition or standard glycaemic markers.
Evidence snapshot
Evidence snapshot
Separate dimensions, not one overall score◎
Human evidenceDeveloping
3/5 evidence depth
✓
Clinical efficacyLimited
2/5 evidence depth
This score reflects completed human outcome evidence. A registered or recruiting trial does not count until results are reported.
◇
Safety evidenceDeveloping
3/5 evidence depth
⌁
Preclinical evidenceStrong
4/5 evidence depth
HOW TO READ THESE SCORESStrong preclinical evidence · developing human evidence
These are editorial evidence-depth ratings on a 1–5 scale, not a statistical result or a single scientific formula. They summarise how much relevant evidence is present in each separate category and how mature that evidence is.
Human evidenceHow much direct research in people is available and how developed it is.
Clinical efficacyWhether human studies demonstrate meaningful outcomes for the claims being discussed.
Safety evidenceHow much human safety, tolerability and longer-term follow-up information is available.
Preclinical evidenceThe depth of laboratory and animal research supporting biological plausibility.
HOW THE EVIDENCE IS ORGANISED
NMN research profile
Research themes are shown separately from the strength of the human evidence so biological interest is not confused with proven clinical benefit.
RESEARCH AREA 01NAD+ levels
RESEARCH AREA 02Metabolic health
RESEARCH AREA 03Energy biology
RESEARCH AREA 04Healthy ageing
Mechanistic and preclinical findings are context for further research; they are not treated as equivalent to demonstrated human outcomes.
From promising signals to human evidencePreclinical research can reveal promising biological signals. Human studies show how far those signals have translated into real-world outcomes.
What people are exploring
COMMUNITY · USE CASES & EXPERIENCE
What people want to change with NMN
NMN is mainly explored for energy, metabolic health and healthy ageing. Human studies show that it can change NAD-related biology; the more important question is whether that consistently improves how people feel or function.
Explore the everyday goalsConceptual scientific illustration
THE PRACTICAL ATTRACTION
The goals behind the interest
What the desired change means in daily life, and what makes an experience useful to understand.
Everyday stamina rather than a stimulant effect
People are interested in sustained energy for work, walking and ordinary activity. The attraction is supporting NAD-related metabolism, with the hope that cellular changes translate into something they can actually feel.
- What makes a report informative
- Function during the same daily activities over time.
- What can muddy the picture
- Sleep, exercise habits and expectancy can alter perceived energy.
Metabolic health and exercise tolerance
Interest includes better glucose handling and feeling more capable during exercise. These goals are related but require different observations: a workout impression does not establish improved insulin sensitivity.
- What makes a report informative
- Comparable exercise performance and relevant clinical measurements.
- What can muddy the picture
- Diet, training and baseline metabolic health affect the result.
Maintaining vitality with age
Healthy-ageing interest focuses on staying active and capable for longer. It is appealing because NAD metabolism is linked to ageing biology, but that does not make an individual vitality report a longevity outcome.
- What makes a report informative
- Specific functional changes rather than a broad anti-ageing claim.
- What can muddy the picture
- A rise in an NAD-related biomarker is not proof of longer life.
PUT THE EXPERIENCE IN CONTEXT
How the goals compare with the research
Open an area to distinguish human findings from laboratory explanations.
More everyday energy
Human findings & limits
Human trials show target engagement more consistently than a dependable improvement in fatigue or daily energy.
Laboratory & animal context
NAD+ is central to cellular energy metabolism, giving the claim a strong biological foundation.
What this means: Biologically plausible, but not a guaranteed noticeable effect.
Better glucose handling
Human findings & limits
A small trial in postmenopausal women with prediabetes improved skeletal-muscle insulin sensitivity without broad improvement across every metabolic measure.
Laboratory & animal context
NAD-related pathways influence mitochondrial and insulin-signalling biology.
What this means: An encouraging group-specific signal that needs broader replication.
Slower ageing
Human findings & limits
No human trial has shown that NMN extends life or broadly slows ageing.
Laboratory & animal context
Animal longevity and healthspan research drives much of the interest.
What this means: A research hypothesis, not an established human outcome.
Research sources and further reading
Dose & duration
DOSE & DURATION
Research protocols · community patterns · calculator toolsSee the numbers in their proper context
See the amount, how often it was used and how long each study ran. Published human research and community descriptions each carry their own source label, so you can see where the numbers came from.
Source matters. The figures below show authorised, human-research or community-described protocols in their original context — not a personalised recommendation.
Published NMN studies use research protocols that vary by population and endpoint; these should not be treated as a general wellness dosing standard.
PUBLISHED HUMAN RESEARCH
View source ↗Prediabetes insulin-sensitivity trial ↗
Postmenopausal women with prediabetes who were overweight or obese
WHAT THIS TRIAL EXAMPLE SHOWS
This was a published human study. It involved Postmenopausal women with prediabetes who were overweight or obese. Route: Taken by mouth. The study lasted 10 weeks. The figures below describe the research design, not a personal schedule.
| First amount studied | 250 mg/day |
|---|---|
| How often? | Daily |
| How was it given? | Taken by mouth |
| How long? | 10 weeks |
See the exact study wording +
Start / initial: 250 mg/day
End / target: 250 mg/day
Frequency: Daily
Route: Oral
Study duration: 10 weeks
Research protocol from a small randomized trial; not a personalised recommendation.
COMMUNITY DISCUSSION
Supplement discussion · trial doses varyWhat people commonly discuss
STARTING APPROACHES
250 mg once daily is a common lower starting amount and matches the dose used in a small randomized insulin-sensitivity trial.
DURATION / CYCLES
Community use commonly sits around 250–500 mg daily for eight-to-twelve weeks before reviewing whether there is a noticeable benefit.
MAINTENANCE DISCUSSION
Some people continue longer or use up to 1,000 mg daily, but an evidence-based long-term maintenance dose has not been established.
Community patterns are anecdotal and unvalidated unless a linked human study independently supports the same approach.
CALCULATOR TOOLS
Work with the numbers
Convert amounts, concentration, liquid volume and vial requirements. These tools do the arithmetic; they do not select a dose.
NEED HELP READING THE NUMBERS?Source labels, routes and dose termsOpen guide +
HOW WE LABEL NUMBERSKnow where a dose came from before you compare it.
Authorised labelHuman trialCommunity-describedBEFORE THE NUMBERS: CHECK THE PRODUCT
Understand peptide testing →A dose only means something if the vial contains what the label says.
Purity, identity, quantity, sterility and endotoxin testing answer different questions. Learn how to read a COA and why a high purity percentage is not the same as confirming the amount in the vial.
READ THIS PAGE IN THREE STEPS
Understand the study before the number
A dose only makes sense alongside the population, route, frequency and duration. Start with where the number came from, then look at how it was delivered and how long the study actually ran.
1Source
Was it an authorised label, a human trial or a community-described pattern?
2Route & frequency
How was it given, and how often? The same number by a different route may not mean the same exposure.
3Duration
Was this one dose, a short trial or long-term treatment? A study window is not automatically a recommended cycle.
ROUTES EXPLAINED
Plain-English guideWhat do the injection types mean?
Route means how a compound was delivered. It affects absorption and can completely change how a study should be interpreted.
SubQ / SCSubcutaneous
An injection into the fatty layer just under the skin.
Common in peptide and metabolic-drug studies. It usually aims for systemic absorption rather than treating only the spot injected.IMIntramuscular
An injection into muscle tissue.
Muscle can absorb a medicine differently from fat. An IM amount should not be assumed to be equivalent to a SubQ amount.IVIntravenous
Delivered directly into a vein.
This gives immediate bloodstream exposure and is commonly used in supervised research or clinical settings. It is not interchangeable with a home injection route.INIntranasal
Delivered through the nose rather than by injection.
The amount delivered depends on formulation and device. A spray count alone does not tell you the dose unless concentration and spray volume are known.Other routes you may see:Oral = swallowed.Topical = applied to skin or another surface.Implant = a formulation placed under the skin by a trained professional.
CALENDAR SETUP
Oral human-study example
Human trial · specific study populationThis study used 250 mg daily for ten weeks in postmenopausal women with prediabetes who were overweight or obese. It is a study record, not an established anti-ageing dose for everyone.
Form and route: Oral NMN
| Calendar stage | Amount each time |
|---|---|
| Weeks 1–10 | 250 mg |
Frequency: Every day · 1 entry per scheduled day.
The calendar copy ends after the ten-week study period.
PLAIN-ENGLISH GLOSSARYWhat do the dose terms mean?Open glossary +
mgmilligram
One thousand micrograms (mcg).
mcg / μgmicrogram
One thousandth of a milligram.
mcg/kgweight-based dose
The amount is calculated for each kilogram of body weight.
IUinternational unit
A measure of biological activity used for some medicines; it cannot be converted to mg without compound-specific information.
Routehow it was given
For example SubQ, IM, IV, intranasal, oral or topical.
Frequencyhow often
For example once daily, twice weekly or every seven days.
Titrationplanned step-up or step-down
A protocol changes the amount over time rather than using one fixed amount throughout.
Half-lifehow quickly levels fall
The time taken for the amount of a compound in the body to reduce by roughly half. It can influence study timing but does not by itself define a schedule.
Cyclea defined period of use
Usually means an on-period followed by a stop or review. Many community 'cycles' have not been clinically validated.
Maintenancea continuing phase
A longer-term amount or interval used after an initial phase when a study or authorised treatment actually defines one.
Reconstitutionturning powder into solution
Adding a specified liquid to a freeze-dried vial so a concentration can be calculated.
U-100 unitssyringe volume markings
100 units equals 1 mL on a U-100 insulin syringe. The markings show volume, not peptide mass.
Safety context
SAFETY & UNCERTAINTY
Short trials are reassuring; long-term healthy-ageing use is less certain
What the current evidence saysPublished human studies are generally small and short. They provide useful tolerability information but cannot settle multi-year safety, interactions, cancer-relevant questions or the quality of every retail supplement.
01 · OBSERVEDPublished safety findings
The summary above reflects the human or preclinical evidence currently represented on this profile.
02 · UNCERTAINGaps still matter
Limited follow-up, small studies or absent controlled trials can leave uncommon and longer-term risks unresolved.
03 · CONTEXTProduct and regulatory status
Route, product identity, quality and regulatory status can materially change the safety context; see the linked status sources below.
Why this matters
NAD precursors are not interchangeable, and supplement purity and stated dose can vary. New symptoms or use alongside treatment for diabetes, cancer or liver disease deserves professional review.
Sources & current status
READ FURTHER
Sources & current status
Follow the professional sources used across this profile, then see how the compound is currently described in regulatory and research terms.
KEY RESEARCH RECORD
3 sourcesSources used on this profile
Peer-reviewed human trialNicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic womenScience ↗Bibliographic recordNicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic womenPubMed ↗Trial registryNicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic womenClinicalTrials.gov ↗
CURRENT STATUS
How to interpret its position today
Developing supplement research
Human studies demonstrate biological effects and short-term exposure, but no authorised anti-ageing or longevity indication.
Science trial · DOI ↗Profile reviewed against its linked source record on 20 September 2026. See how evidence is assessed.